A Simon Pickard1, Maria C De Leon, Thomas Kohlmann, David Cella, Sarah Rosenbloom. 1. Center for Pharmacoeconomic Research and Department of Pharmacy Practice, College of Pharmacy, University of Illinois at Chicago 60612, and Midwest Center for Health Services and Policy Research, Hines VA Hospital, Hines, Illinois, USA. pickard1@uic.edu
Abstract
OBJECTIVE: The objectives of this study were: 1) to determine whether expanding the number of levels (ie, response categories) on the standard 3 level EQ-5D (EQ-5D-3L) to 5-levels (EQ-5D-5L) would improve the descriptive richness and ability of the measure to discriminate among different levels of health, and 2) to examine the psychometric properties of each EQ-5D version in patients with cancer. METHODS: U.S.-based cancer patients self-assessed their health using EQ-5D-3L and EQ-5D-5L. These versions were compared in terms of ceiling effects, convergent validity based on correlations with ECOG performance status and FACT-G, discriminative ability using Rasch analysis, and informational richness using Shannon's Evenness Index (J'). RESULTS: A ceiling effect was observed among a greater proportion of respondents to EQ-5D-3L, n=74/424 (17%), compared with EQ-5D-5L, n=47/424 (11%). Within the midlevel of EQ-5D-3L (some problems), substantial partitioning of the sample into the 3 nonextreme levels of the EQ-5D-5L was observed across dimensions. EQ-5D-5L demonstrated a trend towards slightly stronger correlations with ECOG performance status compared with EQ-5D-3L for all dimensions of health, ie, rs (5L/3L): rmobility=0.38/0.31; rself-care=0.35/0.31; rusual activities=0.55/0.47; rpain/discomfort=0.43/0.37; ranxiety/depression=0.23/0.16; rcrude summary score=0.56/0.49. EQ-5D-5L demonstrated a greater relative efficiency and ability to discriminate different levels of health. Informational richness and evenness of EQ-5D-5L was slightly higher (J'5L=0.75) than EQ-5D-3L (J'3L=0.69). CONCLUSION: Evidence supported the validity of both EQ-5D-3L and EQ-5D-5L in cancer. However, results suggest a 5-level classifier system has less ceiling effect and greater discriminative ability with potentially more power to detect differences between groups compared with EQ-5D-3L.
OBJECTIVE: The objectives of this study were: 1) to determine whether expanding the number of levels (ie, response categories) on the standard 3 level EQ-5D (EQ-5D-3L) to 5-levels (EQ-5D-5L) would improve the descriptive richness and ability of the measure to discriminate among different levels of health, and 2) to examine the psychometric properties of each EQ-5D version in patients with cancer. METHODS: U.S.-based cancerpatients self-assessed their health using EQ-5D-3L and EQ-5D-5L. These versions were compared in terms of ceiling effects, convergent validity based on correlations with ECOG performance status and FACT-G, discriminative ability using Rasch analysis, and informational richness using Shannon's Evenness Index (J'). RESULTS: A ceiling effect was observed among a greater proportion of respondents to EQ-5D-3L, n=74/424 (17%), compared with EQ-5D-5L, n=47/424 (11%). Within the midlevel of EQ-5D-3L (some problems), substantial partitioning of the sample into the 3 nonextreme levels of the EQ-5D-5L was observed across dimensions. EQ-5D-5L demonstrated a trend towards slightly stronger correlations with ECOG performance status compared with EQ-5D-3L for all dimensions of health, ie, rs (5L/3L): rmobility=0.38/0.31; rself-care=0.35/0.31; rusual activities=0.55/0.47; rpain/discomfort=0.43/0.37; ranxiety/depression=0.23/0.16; rcrude summary score=0.56/0.49. EQ-5D-5L demonstrated a greater relative efficiency and ability to discriminate different levels of health. Informational richness and evenness of EQ-5D-5L was slightly higher (J'5L=0.75) than EQ-5D-3L (J'3L=0.69). CONCLUSION: Evidence supported the validity of both EQ-5D-3L and EQ-5D-5L in cancer. However, results suggest a 5-level classifier system has less ceiling effect and greater discriminative ability with potentially more power to detect differences between groups compared with EQ-5D-3L.
Authors: Chun Fan Lee; Raymond Ng; Nan Luo; Nan Soon Wong; Yoon Sim Yap; Soo Kien Lo; Whay Kuang Chia; Alethea Yee; Lalit Krishna; Celest Wong; Cynthia Goh; Yin Bun Cheung Journal: Support Care Cancer Date: 2012-06-06 Impact factor: 3.603
Authors: Martina Garau; Koonal K Shah; Anne R Mason; Qing Wang; Adrian Towse; Michael F Drummond Journal: Pharmacoeconomics Date: 2011-08 Impact factor: 4.981
Authors: Chen-Wei Pan; Hong-Peng Sun; Xingzhi Wang; Qinghua Ma; Yong Xu; Nan Luo; Pei Wang Journal: Qual Life Res Date: 2014-12-25 Impact factor: 4.147
Authors: Meridith E Greene; Kevin A Rader; Göran Garellick; Henrik Malchau; Andrew A Freiberg; Ola Rolfson Journal: Clin Orthop Relat Res Date: 2015-11 Impact factor: 4.176
Authors: Juan Zhu; Xin-Xin Yan; Cheng-Cheng Liu; Hong Wang; Le Wang; Su-Mei Cao; Xian-Zhen Liao; Yun-Feng Xi; Yong Ji; Lin Lei; Hai-Fan Xiao; Hai-Jing Guan; Wen-Qiang Wei; Min Dai; Wanqing Chen; Ju-Fang Shi Journal: Qual Life Res Date: 2020-09-15 Impact factor: 4.147
Authors: Kimberley A Goldsmith; Matthew T Dyer; Martin J Buxton; Linda D Sharples Journal: Health Qual Life Outcomes Date: 2010-06-04 Impact factor: 3.186